| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Alternative Names | Glial Cell Line-Derived Neurotrophic Factor, RET Receptor Tyrosine Kinase |
| Concentration | |
| Conjugate | |
| Form | Lyophilized |
| Formulation | |
| Gene ID | |
| Molecular Weight | |
| Product Type | |
| Reconstitution | |
| Source | Modified recombinant protein, E. coli |
| Storage | |
| Target |
Overview
human GDNF-Biotin is a research-grade protein/peptide reagent used in research settings. It is commonly applied as a tool reagent related to GFRA1 (GDNFR-Alpha-1), RET Receptor Tyrosine Kinase biology and/or assay development. The reagent is provided as a Biotin conjugate, supporting detection or imaging workflows where applicable. It is supplied in Lyophilized format to support flexible downstream use in RUO workflows. Researchers commonly pair it with applications such as Western blot, Live cell imaging, Immunofluorescence, Fluorescence staining, Indirect flow cytometry.
Key elements and design rationale
- Molecular identity: MW: 30.8 kDa (dimer).
- Source / origin: Modified recombinant protein, E. coli.
- Quality attributes: Bioassay tested: Yes; Sterile / endotoxin-free: No.
Modifications
LC-Biotin
When used as a biochemical or pharmacological tool, results are best interpreted relative to the experimental system (species, expression level, and assay readout) and with appropriate negative and competition-style controls where relevant. This product is intended for research use only.
Biological background
Glial-derived neurotrophic factor (GDNF) is a member of the TGF-β superfamily. GDNF signals through a multi-component receptor system, composed of a RET proto-oncogene and one of the four α1-α4 receptors.1 GDNF promotes survival of various neuronal cells, including motoneurons,2,3 Purkinje cells and sympathetic neurons.4 In embryonic midbrain cultures, GDNF promotes the survival and morphological differentiation of dopaminergic neurons and increases their high-affinity DA uptake.5 Cells that express GDNF include Sertoli cells, type 1 astrocytes, Schwann cells,6 neurons, pinealocytes, and skeletal muscle cells.7 In vivo, following transection of facial motor neuron axons, locally applied GDNF has been shown to rescue virtually all damaged neurons from cell death.8 GDNF may be of clinical relevance in the treatment of Parkinson's disease that is characterized by progressive degeneration of midbrain dopaminergic neurons.9,10
Research relevance and current trends
- Using high-specificity ligands, toxins, and engineered peptides to dissect closely related receptor/channel subtypes and signaling microdomains.
- Pairing labeled (e.g., fluorescent) proteins/peptides with advanced imaging to map surface expression, trafficking, and nanoscale organization.
- Increasing emphasis on reproducibility through standardized characterization (identity, purity, and lot QC) and transparent reporting of reagent attributes.
Common research applications
- Western blot: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
- Live cell imaging: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
- Immunofluorescence: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
- Fluorescence staining: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
- Indirect flow cytometry: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
Across these use cases, changes in signal or functional readout are generally interpreted as evidence of differences in target abundance, accessibility, or engagement, but alternative explanations (matrix effects, off-target interactions, or assay artifacts) should be considered.
Notes for experimental interpretation
- Assay context matters: binding assays, functional modulation, and detection workflows can yield different readouts even for the same target system.
- Target complexity: closely related family members, splice variants, and post-translational modifications can influence apparent specificity and potency.
- Matrix and sample effects: buffer composition, detergents, and biological matrices may alter stability or apparent activity; interpret with appropriate controls.
- Control concepts: include negative controls and orthogonal validation (e.g., genetic perturbation or alternative reagents) to support robust interpretation.
Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Henderson, C.E.
et al. (1995) Science266, 1062.
Airaksinen, M.S. Saarma, M.
(2002) Nat. Rev. Neurosci. 3, 383.
Henderson, C.E.
et al. (1994) Science 266, 1062.
Houenou, L.J.
et al. (1996) Cell. Tissue Res. 286, 219.
Kobayashi, M. and Matsuoka, I.
(2000) Neuroreport 11, 2541.
Tomac, A.
et al. (1995) Nature 373, 335.
Zhou, F.Q.
et al. (2003) Cell 113, 814.
Lin, L.F.
et al. (1993) Science 260, 1130.
Matheson, C.R.
et al. (1997) Neuroreport 8, 1739.
Brundin, P.
(2002) Brain 125, 2149.
Grondin, R. and Gash, D.M.
(1998) J. Neurol. 245, P35.
Lin, L.F.
et al. (1993) Science260, 1130.
Lin, L.F.
et al. (1994) J. Neurochem. 63, 758.
